Diabetes Research and Clinical Practice
Volume 64, Issue 1 , Pages 27-32 , April 2004

Transient elevation of liver transaminase after starting insulin therapy for diabetic ketosis or ketoacidosis in newly diagnosed type 1 diabetes mellitus

Received 27 February 2003 ,Revised 25 July 2003 ,Accepted 14 October 2003.

References 

  1. Belfiore F, Napoli E, Vecchio LL. Increased activity of some enzymes in serum in cases of severely decompensated diabetes, with and without ketoacidosis. Clin. Chem. 1972;18:1403–1406
  2. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibododies. N. Engl. J. Med. 2000;342:301–307
  3. Brian EW, Schecher AJ, Persons EL. Unusual glycogen storage in a case of diabetes mellitus. Arch Intern. Med. 1937;59:685–690
  4. Vallance-Owen J. Liver glycogen in diabetes mellitus. J. Clin. Pathol. 1952;5:42–53
  5. Goodman J. Hepatomegaly and diabetes mellitus. J. Clin. Pathol. 1953;5:42–53
  6. Bronstein HD, Kantrowitz PA, Schaffner F. Marked Enlargement of the liver and transient ascites associated with the treatment of diabetic acidosis. N. Engl. J. Med. 1959;261:1314–1318
  7. W.J. Manderson, F.R.C.P.G.M.T. McKiddie, M.R.C.P. Glasgow, D.J. Manners, D.Sc., J.R. Stark, Liver glycogen accumulation in unstable diabetes, Diabetes 17 (1968) 13–16.
  8. Ohno T, Horio F, Tanaka S, Terada M, Namikawa T, Kitoh J. Fatty liver and hyperlipidemia in IDDM (insulin-dependent diabetes mellitus) of streptozotocin-related shrews. Life Sci. 2000;66(2):125–131
  9. World Health Organization, Report of a WHO Study Group Second Report, Genova, Tech. Rep. Ser. 727 (1985) 1–113.
  10. Kimura S. Quantitative estimation of liver–kidney contrast using echo-histogram analysis in diffuse liver diseases and renal diseases. Jpn. J. Med. Ultrasonics. 1986;13:425–433 (Japanese)
  11. Weidman SW, Ragland JB, Fischer JN, Kitabchi AE, Sabesin SM. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. J. Lipid Res. 1982;23:171–182
  12. Joven J, Rubies-Prat J, De La Figuera M. High density lipoprotein changes during treatment of diabetic ketoacidosis. Diabetes Metab. 1985;11:102–105
  13. Foster DW, McGarrry JD. The metabolic derangements and treatment of diabetic Ketoacidosis. N. Engl. L. Med. 1983;309:159–169
  14. Fleischmann M, Ivnedjian PB. Regulation of sterol regulatory-element binding protein 1 gene expression in liver: role of insulin and protein kinase. Biochem. J. 2000;349:13–17
  15. Foretz M, Pacot C, Dugail I, Lemarchand P, Guichard C, Lipvre XL, et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol. Cell. Biol. 1999;19:3760–3768
  16. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Gpldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. U.S.A. 1999;96(24):13656–13661
  17. I. Shimomura, Y. Bashmakov, J.D. Horton, Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus, J. Biol. Chem. 274 (42) 30028-30032.

PII: S0168-8227(03)00265-1

doi: 10.1016/j.diabres.2003.10.017

Diabetes Research and Clinical Practice
Volume 64, Issue 1 , Pages 27-32 , April 2004

Article Tools

* Image Usage & Resolution